Asian Spectator

Novaliq and Jiangsu Hengrui Medicine Announce a Strategic Collaboration in Ophthalmology for the EyeSol(R)-based, Investigational Products NOV03 and CyclASol(R) in China

  • Written by ACN Newswire - Press Releases
Heidelberg, Germany, Nov 9, 2019 - (ACN Newswire) - Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, and Jiangsu Hengrui Medicine Co., Ltd. (SSE: 600276), a fully integrated biopharmaceutical company based in China, announce today the closing of an exclusive license agreement to develop, manufacture and commercialize the innovative, water-free drugs NOV03 and CyclASol(R) for the treatment of dry eye disease in the People's Republic of China (including mainland China, Hong Kong, Macau and Taiwan).

image

Novaliq - Logo

To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/6655/49568_enh.jpg

Dry eye disease (DED) is a chronic and serious disease of the ocular surface that negatively impacts quality of life comparably to other severe diseases. Patients present symptoms such as a feeling of dryness, burning, foreign body sensation or pain and report impairment of social functioning. Visual function-related manifestations including fluctuating vision with blinking, blurred vision and difficulty with reading, despite normal visual acuity, are important and underestimated aspects of the disease.

Eighty-six percent of patients with dry eye show signs of Meibomian gland dysfunction (MGD). NOV03 (perfluorohexyloctane) is being developed as a treatment for patients with dry eye disease associated with Meibomian gland dysfunction and has a novel mode of action that has been confirmed in various studies. Several clinical trials have demonstrated that NOV03 stabilizes the tear film lipid layer and protects from excessive evaporation. In addition, it has been shown to penetrate into the meibomian glands and liquefy secretions there, improving the quality of the meibum and the tear film lipid layer. NOV03 is being developed in phase three for the treatment of dry eye disease associated with Meibomian gland dysfunction (MGD) in the USA.

CyclASol(R) is an anti-inflammatory investigational drug for patients with moderate to severe DED with an inflammatory disease component. CyclASol(R) contains cyclosporine A 0.1% in EyeSol(R) and holds the promise of unfolding cyclosporine A's full potential on the ocular surface, enabling clinicians to treat more patients successfully. CyclASol(R) is in phase three development for the treatment of dry eye disease in the USA.

Both investigational drugs have shown in their recent late-stage clinical trials superior efficacy results, with an early onset of action and an excellent tolerability profile. They are perceived as breakthrough medicines for dry eye patients worldwide with an unprecedented benefit-risk profile.

"Dry eye disease is common in China, but treatment options are very limited in China. We are committed to serving this unmet need and feel excited about the partnership with Novaliq, a leading company in ophthalmology with the world's first water-free eye drop platform. We shall work closely together with Novaliq to allow patients in China to benefit from this platform," said Piaoyang Sun, Chairman of the Board of Hengrui Medicine.

"We are excited about this strategic collaboration with Jiangsu Hengrui Medicine. We believe that Jiangsu Hengrui Medicine, as a leading biopharmaceutical company in China, is the ideal partner for us to maximize the commercial potential of our innovative products NOV03 and CyclASol(R) in the Chinese market," said Christian Roesky, PhD, CEO of Novaliq. "With great benefits in terms of efficacy and tolerability, NOV03 and CyclASol(R) can make a huge difference to the life of dry eye patients. We look forward to working with the team of Jiangsu Hengrui Medicine to bring these breakthrough medicines, if approved, to physicians and patients in the second biggest healthcare market in the most timely, efficient and effective way possible."

Under the terms of the agreement, Novaliq is eligible to receive an upfront payment of up to $9 million and up to $156 million in milestone payments linked to pre-defined development, regulatory and commercialization objectives. In addition, Jiangsu Hengrui Medicine will be obligated to pay Novaliq tiered percentage royalties on net sales of NOV03 and CyclASol(R) in China. Thus, Jiangsu Hengrui Medicine secures exclusive rights to develop, manufacture and commercialize both drugs in China. Jiangsu Hengrui Medicine will be responsible for all development, regulatory and commercialization activities and related expenses in the territory.

About Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd. established in 1970, is a leading biopharmaceutical company based in China with annual net sales of about $2.5 billion in 2018. Hengrui is devoted to empowering healthier lives through research, with capabilities across oncology, immunology, anesthesiology, cardiovascular diseases, metabolic diseases, and pain management. Hengrui has more than 140 clinical trials ongoing worldwide and an in-house sales force covering more than 18,000 hospitals in China.

About Novaliq

Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol(R), the worldwide first water-free eye drop technology. Novaliq offers an industry-leading portfolio addressing today's unmet medical needs of millions of patients with eye diseases. Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in Life and Health Sciences companies. More on www.novaliq.com.

Important notice: NOV03 and CyclASol(R) are investigational new drugs. NOV03 and CyclASol(R) are in late-stage clinical evaluation in the U.S. with an open IND by the U.S. Food and Drug Administration.

Media contact for Novaliq:Heidrun Kirsch, VP Marketing, Novaliq GmbH, media@novaliq.com

Media contact for Jiangsu Hengrui Medicine:Xiaohan Liu, Secretary of the Board, Jiangsu Hengrui Medicine Co., Ltd., liuxiaohan@hrs.com.cn

Sources:- Schiffman RM, Walt JG, Jacobsen G, et al. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110(7):412-9- Nelson JD, Craig JP, Akpek EK, Azar DT, Belmonte C, Bron AJ, et al. TFOS DEWS II Introduction. Ocul Surf. 2017;15(3):269-275- Koh S. Mechanisms of visual disturbance in dry eye. Cornea. 2016;35(11): S.83-8- Lemp et al. 2012; Cornea 31: 472-8

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49568

Copyright 2019 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Servier Completes the Acquisition of Symphogen

PARIS, June 4, 2020 /PRNewswire-AsiaNet/ -- Servier, an independent international pharmaceutical company, today announced that it has completed the acquisition of Symphogen A/S.Symphogen wil...

SiriusXM Adds Australian Football League Matches, Weekly Show ...

NEW YORK, June 5, 2020 /PRNewswire-AsiaNet/-- - Renowned Australian commentator and AFL Club President Eddie McGuire to host "Aussie Football Rules America with Eddie McGuire" every Thursday...

Huawei OceanStor Dorado All-Flash Storage Wins Best of Show Aw...

TOKYO, June 4, 2020 /PRNewswire-AsiaNet/ -- At Interop Tokyo 2020, the largest ICT exhibition in Japan, the Huawei next-gen OceanStor Dorado All-Flash Storage officially earned plaudits from...

DERMALOG Fever Check at the Wiesbaden Casino

WIESBADEN and HAMBURG, Germany, June 4, 2020 /PRNewswire-AsiaNet/ -- - After a mandatory corona break of several weeks, casinos and gambling resorts in Germany are reopening. Operators have ...

Vuse and Vype Expand Subscription Services Providing Convenien...

LONDON, June 4, 2020 /PRNewswire-AsiaNet/ -- - The BAT owned E-Cigarette Brands Launch Subscription Services in the US and UKVuse and Vype, global e-cigarette brands, have launched a persona...

REDUIT: Radical Innovation in a User Friendly Format

NEUCHATEL, Switzerland, June 4, 2020 /PRNewswire-AsiaNet / -- Intuitive and simple product design is center-stage for the Swiss beauty tech innovator REDUIT.The company has gone to great len...

Eisai: Brain Performance (Brain-Health) Self-Check Tool NouKNOW to be Used in Beauty Salons

TOKYO, Jun 4, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the digital tool for self-assessment of brain performance (brain health) "NouKNOWTM" (pronounced "NOH-NOH", non- m...

Singapore's LABMED shipped over 20 million masks to meet global demand

SINGAPORE, Jun 4, 2020 - (ACN Newswire) - Singapore based LABMED is playing a crucial role in supplying medical masks and medical personal protective equipment (PPE) globally, to countries ...

Expert Webinar of the 2nd conference of Global Health Forum of...

BEIJING, June 4, 2020 /PRNewswire-AsiaNet/ -- On June 2, the Boao Forum for Asia (BFA) held the expert webinar of the 2nd conference of Global Health Forum of Boao Forum for Asia (GHF). The ...

Huawei Atlas 900 AI Cluster Wins the Only Best of Show Award f...

TOKYO, June 4, 2020 /PRNewswire-AsiaNet/ -- The jury panel at Interop Tokyo 2020 has given the Huawei Atlas 900 AI cluster the Best of Show Award in recognition of its powerful AI computing ...

NEC's Netcracker 2020 Puts Service Providers at the Center of the Digital Economy

WALTHAM, MA, Jun 4, 2020 - (JCN Newswire) - Netcracker Technology, a wholly owned subsidiary of NEC Corporation, announced today the launch of its Netcracker 2020 portfolio to help service ...

Konstantin Chaykin: New Mars Conqueror Mk3 Fighter Watch Is La...

MOSCOW, June 4, 2020, /PRNewswire-AsiaNet/-- The prospect of flying to Mars has never been closer. Konstantin Chaykin is certain that the conquest of Mars necessitates the thinking over of m...

WARC Awards 2020 - Effective Use of Brand Purpose winners announced

LONDON, Jun 4, 2020 - (ACN Newswire) - Campaigns for global brands including Airbnb, Cadbury Dairy Milk, Finish, Harpic and L'Oreal, as well as local brands such as Hungarian Telekom, Maxis...

Singapore's LABMED shipped over 20 million masks to meet global demand

Rising Singapore medical equipment company has been supplying much needed masks, PPEs to Covid-19 hotspots worldwide SINGAPORE - Media OutReach - 4 June 2020 - Singapore...

COOCAA TV Bounce Back Sale | Up to 50% Off on Lazada Philippines

MANILA, PHILLIPINES - ACCESSWIRE - June 4, 2020 -We all know that we should be staying safe at home. What better way to spend time at home than watching Netflix on TV and what better TV t...

COOCAA TV Bounce Back Sale | Up to 50% Off on Lazada Philippines

MANILA, PHILLIPINES - ACCESSWIRE - June 4, 2020 -We all know that we should be staying safe at home. What better way to spend time at home than watching Netflix on TV and what better TV t...

Getac's Brand New, 5G-compatible B360 Laptop Combines Best-in-...

TOKYO, June 4, 2020 /PRNewswire-AsiaNet/ -- - Industry-leading features, connectivity, and build quality come together in powerful new fully rugged solution Getac has today unveiled its B360...

Bityard Exchange Garners Global Attention since its April Launch

SINGAPORE, Jun 4, 2020 - (ACN Newswire) - Bityard, a world leading digital contract exchange, has garnered widespread attention from industry insiders and experts since its launch in April ...

Userlytics Launches "Instant Access" Recorder for Remote User ...

AUSTIN, Texas, June 4, 2020 /PRNewswire-AsiaNet/ -- -- The new capability will enable remote moderation of usability tests and market research interviews with instant remote participant acce...



News Company Media Core

Content & Technology Connecting Global Audiences

More Information - Less Opinion